Evidence map›Paper›PMID 40420575›Full record

ArticleCancer biomarkers : section A of Disease markers2025

The change of soluble programmed cell death ligand-1 (sPD-L1): A new predictor of prognosis in hypopharyngeal squamous cell carcinoma patients treated with radiotherapy.

Zihan Zhou, Xingchen Ding, Xinbin Bai, Jia Yang, Jin Xu, Juan Xu, Yunhao Chen, Shumei Jiang, Man Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zihan ZhouDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Xingchen DingDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Xinbin BaiDepartment of Oncology, Jining Tumor Hospital, Jining, Shandong, China.
Jia YangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jin XuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Juan XuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yunhao ChenDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Shumei JiangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Man HuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PurposeThe aim of this study was to evaluate the concentration of soluble programmed cell death ligand-1 (sPD-L1) in the plasma of hypopharyngeal squamous cell carcinoma (HSCC) patients before and after radiotherapy (RT) and to explore its correlation with prognosis.MethodsA total of 47 patients and 12 healthy individuals were enrolled. All blood samples were collected before RT and 35 blood samples were obtained after RT. Twenty-three matched Formalin-fixed paraffin-embedding (FFPE) specimen from patient tumor biopsies were examined PD-L1 immunohistochemistry, and the sPD-L1 levels were quantified by enzyme-linked immunosorbent assay (ELISA).ResultsThe level of plasma sPD-L1 in patients were higher than healthy individuals. Plasma sPD-L1 level at diagnosis correlated positively with T stage. The plasma sPD-L1 concentration had moderate correlations with PD-L1 expression in tissue (tPD-L1). In addition, the study proved that patients with high sPD-L1 had significantly worse overall survival (OS) than patients with low sPD-L1. sPD-L1 levels before RT was the unique independent prognostic factors for OS.ConclusionsThe study reported that sPD-L1 concentration before RT is proportional to the expression of tPD-L1. Besides, sPD-L1 before RT and tPD-L1 may serve as useful biomarkers for prognosis.

Indexed as

B7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellHypopharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisB7-H1 AntigenBiomarkers, TumorCD274 protein, humanhypopharyngeal squamous cell carcinomaPD-L1prognosisradiotherapysPD-L1

Identifiers

PMID40420575
PMCPMC12288420

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.